– Clinical Trials and Therapeutics
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are two neurodegenerative cause of dementia, in which patients are generally treated with Cholinesterase inhibitors. This is an NIHR Health Technology Assessment funded international multi-centre trial examining the efficacy of combined treatment with Memantine. The Southampton site for this trial is the Memory Assessment and Research Centre, Moorgreen Hospital.